WASHINGTON, D.C.—Ogilvy Public Relations Worldwide and WPP sister company Shire Health Group have established Fast4wD Ogilvy, a clinical trial recruitment and retention firm devoted to addressing the pharmaceutical industry’s need for global clinical trial support. The new offering brings together the health communications and patient advocacy expertise of Ogilvy’s Washington office with the extensive clinical trial support capability in Europe and Asia of Shire’s existing specialty company, Fast4wD, UK.
The result, according to Ogilvy PR CEO Marcia Silverman, is “the first marketing company ever able to offer full specialized patient recruitment and retention support for clinical trials worldwide.”
Fast4wD Ogilvy will work with pharmaceutical companies that need global support for clinical trials. More and more pharmaceutical companies are seeking to conduct their clinical trials both in the U.S. and overseas.
“There is a rapidly growing need which requires a seamless global approach,” says Shire Health Group CEO Gloria Gibbons. “Several years ago the Shire Health Group created Fast4wD, a specialized patient recruitment and retention clinical communications agency, with capability in Europe and Asia. Because of the success we have been experiencing in those markets, many of our clients have been asking for additional U.S. solutions to meet their global needs. We are delighted to now be in a position to do just that.”
Emma Sergeant, managing director of Fast4wD, UK, and president worldwide of the new venture said, “Pharmaceutical companies are experiencing significant delays in the clinical development process. The most significant bottleneck is due to difficulties with identifying, enrolling, and retaining suitable patients for the clinical trials required for product registration. Fast4wD Ogilvy’s global services have been set up to address this need.”
Fast4wD Ogilvy will maintain offices in Washington, D.C., and Oxford in the U.K. Chris Shreeve, Ogilvy senior vice president, will head up the Washington office. Michelle Argument will head the Europe/Asia operation.